Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma

Yousheng Mao, Zhentao Yu, Bin You, Wentao Fang, Brian Badgwell, Mark F. Berry, DuyKhanh P. Ceppa, Chun Chen, Haiquan Chen, Miguel A. Cuesta, Xavier Benoit D’Journo, Guy D. Eslick, Jianhua Fu, Xiangning Fu, Shugeng Gao, Jianxing He, Jie He, Yunchao Huang, Gening Jiang, Zhongmin Jiang, Jae Y. Kim, Danqing Li, Hui Li, Shanqing Li, Deruo Liu, Lunxu Liu, Yongyu Liu, Xiaofei Li, Yin Li, Weimin Mao, Daniela Molena, Christopher R. Morse, Nuria M. Novoa, Lijie Tan, Qunyou Tan, Alper Toker, Ti Tong, Qun Wang, Benny Weksler, Lin Xu, Shidong Xu, Tiansheng Yan, Lanjun Zhang, Xingyi Zhang, Xun Zhang, Zhu Zhang, Xiuyi Zhi, Qinghua Zhou


Esophageal cancer (EC) is a highly prevalent malignancy in China. According to the data released by National Cancer Registry Center of China in 2015, the prevalence of EC was 21.17/100,000 in China in 2012, ranking fifth among all malignancies; the mortality rate was 15.58/100,000, ranking fourth. It is expected that there will be 477,900 new EC cases nationwide in 2015, whereas 375,000 people will die from EC (1,2). Worldwide, EC is the 8th most common malignancy, with 416,000 new cases in 2012 (3). At present, EC treatment is based on multidisciplinary treatment, but surgery remains the most effective therapy in optimizing long-term prognosis in patients without metastatic disease. The ideal surgical approach is a matter of debate.

Download Citation